Results 111 to 120 of about 3,389 (131)

Imipenem/Relebactam Ex Vivo Clearance During Continuous Renal Replacement Therapy

open access: yesAntibiotics, 2021
(1) Purpose of this study: determination of adsorption and transmembrane clearances (CLTM) of imipenem and relebactam in ex vivo continuous hemofiltration (CH) and continuous hemodialysis (CHD) models.
Bruce Mueller   +2 more
exaly   +2 more sources

Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.

open access: yesAntimicrobial Agents and Chemotherapy, 2018
The imipenem-relebactam combination is in development as a potential treatment regimen for infections caused by Enterobacteriaceae possessing complex β-lactamase backgrounds.
Robert A Bonomo   +2 more
exaly   +2 more sources

Global Resistance of Imipenem/Relebactam Against Gram-Negative Bacilli: Systematic Review and Meta-Analysis

open access: yesCurrent Therapeutic Research
BACKGROUND: Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C beta-lactamase inhibitor, including KPC from Klebsiella pneumoniae.
Reza Abniki, Amirhossein Tashakor
exaly   +2 more sources
Some of the next articles are maybe not open access.

Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.

Clinical Infectious Diseases, 2022
Daria Van Tyne   +2 more
exaly  

Activities of Imipenem-Relebactam Combination Against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Journal of Microbiology, Immunology and Infection, 2022
I-Ling Lin   +2 more
exaly  

Activity of Imipenem-Relebactam Against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.

Antimicrobial Agents and Chemotherapy, 2020
José A Oteo   +2 more
exaly  

In Vitro Development of Imipenem/Relebactam Resistance in KPC-Producing Klebsiella pneumoniae Involves Multiple Mutations Including OmpK36 Disruption and KPC Modification

International Journal of Antimicrobial Agents, 2023
Concepcion Gonzalez-bello   +2 more
exaly  

Home - About - Disclaimer - Privacy